title: [Cefixime therapy in patients with proven gonorrhea].
abstract: Cefixime is a new third generation oral cephalosporin that exhibits excellent antibacterial activity against Neisseria gonorrhoeae, including beta-lactamase-positive strains. In an open uncontrolled clinical trial 14 male patients suffering from acute gonorrhea, aged 23 to 48 years, were treated with a single dose of 400 mg of cefixime. All 13 fully evaluable patients were clinically and bacteriologically cured. Side effects were not reported.
authors.forename: A
authors.initials: A
authors.lastname: Backhaus
authors.forename: J
authors.initials: J
authors.lastname: Tinzl
mesh_terms: D000208:Acute Disease; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020682:Cefixime; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004361:Drug Tolerance; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000890:Anti-Infective Agents; D020682:Cefixime; D002439:Cefotaxime
vernacular_title: Cefiximtherapie bei Patienten mit nachgewiesener Gonorrhoe.